Biosimilar drugs often translate to lower provider profits, says Navigant analysis

Posted on

One of the main culprits is the "buy-and-bill" reimbursement model for infused therapies.

from Healthcarecare Finance News Feed http://www.healthcarefinancenews.com/news/biosimilar-drugs-often-translate-lower-provider-profits-says-navigant-analysis

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s